Choate Investment Advisors’s KalVista Pharmaceuticals KALV Stock Holding History

Choate Investment Advisors’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$201K	Hold	10,000	–	–	﹤0.01%	429
2025 Q4	$162K	Hold	10,000	–	–	﹤0.01%	434
2025 Q3	$122K	Hold	10,000	–	–	﹤0.01%	420
2025 Q2	$113K	Hold	10,000	–	–	﹤0.01%	418
2025 Q1	$115K	Hold	10,000	–	–	﹤0.01%	390
2024 Q4	$84.7K	Hold	10,000	–	–	﹤0.01%	399
2024 Q3	$116K	Hold	10,000	–	–	﹤0.01%	380
2024 Q2	$118K	Hold	10,000	–	–	﹤0.01%	376
2024 Q1	$119K	Hold	10,000	–	–	﹤0.01%	403
2023 Q4	$123K	Hold	10,000	–	–	﹤0.01%	373
2023 Q3	$96.3K	Hold	10,000	–	–	﹤0.01%	377
2023 Q2	$90K	Buy	+10,000	New	+$92.2K	﹤0.01%	303

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Choate Investment Advisors's KALV Position: Q1 2026 in Review

Choate Investment Advisors held its KalVista Pharmaceuticals (KALV) position steady in Q1 2026 at 10,000 shares worth $201K. The position accounts for ﹤0.01% of the portfolio, ranked #429.

Choate Investment Advisors first reported a position in KALV in Q2 2023 and has held it in 12 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

Choate Investment Advisors held 10,000 shares of KalVista Pharmaceuticals worth $201K as of Q1 2026.
Choate Investment Advisors left its KalVista Pharmaceuticals share count unchanged in Q1 2026.
KalVista Pharmaceuticals made up ﹤0.01% of Choate Investment Advisors's portfolio in Q1 2026, its #429 holding.
Choate Investment Advisors first reported a position in KalVista Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Choate Investment Advisors's 13F filing for Q1 2026, filed 13 May 2026.